Treatment of hepatitis C in the patient with decompensated cirrhosis

Current Hepatitis Reports

Volumn 12, Issue 4, 2013, Pages 236-245

  Everson, Gregory T ^a   Bhatt, Asmeen ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antiviral therapy; Boceprevir; Cirrhosis; Daclatasvir; Hepatitis C; Interferon; Liver transplantation; Simeprevir; Sofosbuvir; Telaprevir

Indexed keywords

BOCEPREVIR; DACLATASVIR; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL OUTCOME; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; RISK REDUCTION; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; VIRUS LOAD;

EID: 84883450412     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-013-0181-7     Document Type: Article

References (50)

1. Wiesner RH et al. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9(11):S1-9.
2. Ghany MG et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4): 1433-44. Good review of treatment options for HCV in 2011.
3. Kornberg A et al. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C. Transplantation. 2008;86(3):469-73.
4. Roche B, Samuel D. Hepatitis C virus treatment pre-and post-liver transplantation. Liver Int. 2012;32 Suppl 1:120-8.
5. Saxena V, Terrault N. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant. 2012;17(3):216-24.
6. Selzner N et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88(10):1214-21.
7. Ghany MG et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
8. Everson GT et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42(2):255-62.
9. Bacon BR et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17.
10. Jacobson IM et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-16.
11. Poordad F et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206.
12. Sherman KE et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl JMed. 2011;365(11):1014-24.
13. Zeuzem S et al. Telaprevir for retreatment of HCVinfection. N Engl J Med. 2011;364(25):2417-28.
14. Fried MW et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-82.
15. Hadziyannis SJ et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-55.
16. Manns MP et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.
17. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. For the accelerate investigators. Peginterferon alfa-2a and ribavirin for 16 or 24weeks in HCV genotype 2 or 3.N Engl J Med. 2007;357: 124-34.
18. Terrault NA et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl. 2007;13(1):122-9.
19. Amarapurkar DN, Patel ND, Kamani P. Antiviral therapy of decompensated cirrhosis due to hepatitis C viral infection. Trop Gastroenterol. 2005;26(3):119-22.
20. Annicchiarico BE et al. Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation. Transplant Proc. 2008;40(6):1918-20.
21. Carrion JA et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol. 2009;50(4):719-28.
22. Crippin JS et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8(4):350-5.
23. Everson GT. Treatment of hepatitis C in the patient with decompensated cirrhosis. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S106-12.
24. Forns X et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003;39(3):389-96.
25. Tekin F et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther. 2008;27(11):1081-5.
26. Thomas RM et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. 2003;9(9):905-15.
27. Londono MC, Crespo G, Carrion JA, Garcia-Retortillo M, Marino Z, Lens S, et al. Efficacy and safety of standard antiviral therapy in cirrhotic patients awaiting liver transplantation (LT). J Hepatol. 2013;58:S69A.
28. Iacobellis A et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol. 2007;46(2):206-12.
29. Everson GT et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57(5):1752-62. Randomized controlled trial of pre-transplant peginterferon/ribavirin to prevent posttransplant recurrence of HCV infection.
30. Giannini EG, Afdhal NH. Eltrombopag in patients with chronic liver disease. Expert Opin Pharmacother. 2013;14(5):669-78.
31. Everson GT et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology. 2006;44(6):1675-84.
32. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl. 2010;16:748-59.
33. Fontaine H, Hezode C, Dorival C, et al. SVR12 rates and safety of triple therapy including telaprevir and boceprevir in 221 cirrhotic non responders treated in the French early access program (ANRS CO20-CUPIC). J Hepatology. 2013;58:S27. A. Largest series on the treatment of HCV in patients with cirrhosis with current boceprevir-and telaprevir-based triple therapy.
34. Rutter K, Ferlitsch A, Maieron A, Strattermayer A, Graziadei I, Dulic M, et al. Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced liver disease-predictive factors for sepsis. J Hepatol. 2013;58:S30A.
35. Saxena V, Catalli L, Wayne E, Terrault N. Protease-inhibitor triple therapy in cirrhotics with compensated and mildly decompensated disease: implications for wait-listed patients. Liver Transplant. 2013;19:S99A.
36. Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, et al. Efficacy of telaprevir dosed twice daily versus every 8 hours by IL28. B genotype: results from the phase III optimize study. J Hepatol. 2013;58:S326A.
37. Verna E.C L.T, Olsen SK et al. High early response rates with protease inhibitor triple therapy in a multicenter cohort of HCV infected patients awaiting liver transplantation. Hepatology 2012;56:218. A. First report of pre-transplant use of current triple therapy to prevent post-transplant recurrence of HCV infection.
38. Burton Jr. JR, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis. 2013;17(1):73.
39. Lawitz E et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87. First report of sofosbuvir as triple therapy for HCV GT1 or in an interferon-free regimen with ribavirin for HCV GT2/3.
40. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-naïve patients: results from QUEST-1. A Phase III Trial. J Hepatol. 2013;58:S574A.
41. Manns M, Marcellin P, Poordad F, de Araujo ES A, Buti M, Horsmans Y, et al. Simeprevir (TMC435) with peginterferon/ ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: results from QUEST-2, a Phase III Trial. J Hepatol. 2013;58:S568A.
42. Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, et al. Faldaprevir plus pegylated interferon Alfa 2. A and ribavirin in chronic HCV genotype 1 treatment-naïve patients: final results from STARTVERSO1, a randomised, double-blind. Placebo-controlled phase III trial. J Hepatol. 2013;58:S569A.
43. Lok AS et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216-24. First report of an interferon-free, ribavirin-free dual DAA regimen to treat HCV GT1 null responders.
44. Poordad F et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45-53. A multi-DAA interferon-free regimen targeting HCV NS3/4a protease, NS5b polymerase, and NS5a protein with >90% SVR.
45. Gane EJ et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34-44.
46. Gane EJ, Stedman CA, Hyland RH, Pang PS, Ding X, Symonds WT, et al. All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCVinfection: the ELECTRON study. J Hepatol. 2013;58:S6A.
47. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). J Hepatol. 2013;58:S570A.
48. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson D, Zeuzem S, et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 ± ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. J Hepatol. 2013;58:S4A.
49. Everson GT, Sims KD, Rodriquez-Torres M, Hezode C, Lawitz E, Bourliere M, et al. Interim analysis of an interferon (IFN)-and ribavirin (RBV)-free regimen of daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in treatment-naïve, hepatitis C virus genotype 1-infected patients. J Hepatol. 2013;58:S573A.
50. Jacobson IM et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20): 1867-77. Sofosbuvir plus ribavirin as interferon-free treatment for HCV GT2/3.